Dublin, Sept. 30, 2019 (GLOBE NEWSWIRE) -- The "Next-Generation Sequencing Market and Survey of NGS Laboratories" report has been added to ResearchAndMarkets.com's offering.

Next-generation sequencing (NGS) technologies encompass the modern, post-Sanger sequencing techniques that revolutionized and expanded the fields of molecular biology and genomics in recent years.

NGS has been a disruptive technology that had a substantial impact on the characterization of the genome of various species and has found numerous applications in a large variety of fields, including clinical diagnostics, drug discovery and development, agriculture, and forensics.

Next-Generation Sequencing Markets provides an in-depth look at the sequencing market, including data for 2018-2023 for the following markets:

• Next-Generation Sequencing Market
• Next-Generation Sequencing Consumables Market
• Next-Generation Sequencing Market by Region: U.S.
• Next-Generation Sequencing Market by Region: Europe
• Next-Generation Sequencing Market by Region: Europe
• Market Size by Application: Diagnostics
• Market Size by Application: Pharmaceuticals

This report includes a Survey of Labs Using Next-Generation Sequencing. The survey was conducted by an experienced NGS market analyst who interviewed lab managers and directors to obtain a real-world viewpoint on the next-generation sequencing market today.

• Please describe the lab's industry and function?
• How many sequencers does the laboratory have, and which models?
• For your most recent sequencers, please describe: the model, what applications are run typically (by percentage), how often or how many samples (runs, samples, slides, flow cells, plates, multiplexed or not).
• Which applications are expected to increase most?
• Does the lab outsource any sequencing? For what reason(s)?
• How does the lab/ organization address regulated patient samples?
• Does the lab have accreditation for regulated patient samples?
• Which sequencers are used for regulated and non-regulated patient samples?
• In what disease areas does the lab sequence regulated/ non-regulated patient/ human samples? What disease areas are expected to grow the most from 2017-2018?
• What percentage of samples sequenced are patient samples subject to regulation, patient/ human samples not subject to regulation, and non-patient/ non-human samples not subject to regulation? How is this expected to change from 2017-2018
• How much is the volume of NGS and capillary sequencing expected to change overall from 2017 to 2018?
• What sequencer features or steps in the sequencing process would you most like to be changed/ improved?
• What is the main bottleneck in your sequencing process (ie at what step do things back up)?
• How challenging are data analysis and data management?
• Which systems would the lab most likely consider for future purchases?
• What is the likely time-frame for future sequencer purchases?
• Which systems are likely to be used in the future for regulated patient samples (and are not being used currently for that)?
• What barriers or other issues would hinder the growth of sequencing, particularly NGS, in clinical areas?

Companies Mentioned

• 10x Genomics Inc.
• Agilent
• BGI
• Bio-Rad Laboratories
• Fluidigm
• Illumina Inc.
• MilliporeSigma
• Mission Bio Inc.
• NanoString Technologies
• New England Biolabs Inc.
• NuGen Technologies Inc.
• Oxford Nanopore Technologies Ltd.
• Promega Corporation
• Qiagen
• Roche
• Swift Biosciences
• Thermo Fisher Scientific

Key Topics Covered

1: Market Analysis & Report Summary

Overall Sequencing Market Revenue

• Regional Breakout
• Market Share

Scope

Methodology

Outline

Demographics

• Regional Distribution of Respondents' Labs
• Industrial Distribution of Respondents' Labs
• Laboratory Function of Respondents' Labs
• Distribution by Number of Sequencers
• Brand(s)/ Types(s) of Sequencers Owned, Overall
• Library Preparation and Other Automation
• Position/ Role of Respondents

2: System Installations

Overall Installed Base

• Distribution of Sequencer Models
• Distribution of Number of Sequencers

Installed Base by Region

• Overall Brand/ Type
• Next-Generation Systems
• Capillary Systems

Installed Base by Industry Segment

• Overall Brand/ Type
• Next-Generation Systems
• Capillary Systems

Installed Base by Laboratory Function

• Overall Brand/ Type
• Next-Generation Systems
• Capillary / Gel Systems

3: Sequencer Applications, Clinical Applications, and Usage Trends

Sequencer Applications and Usage

• Applications Run, Overall and by Brand/ Type
• Likely Increases in Applications and Volume
• Capacity Usage of Systems
• Outsourcing

Clinical Applications

• Sequencing of CLIA Regulated Patient Samples
• Certification for Regulated Samples
• Sequencers Used or Planned for Patient/ Human Samples
• Disease/ Therapeutic Areas Where Sequencing Applied
• Challenges for Growth of Clinical Sequencing

4: Preferences & Evaluations

Key Criteria for Choosing Sequencers

• Overall
• By Next-Generation Systems vs Capillary Systems

Changes or Improvements

Bottlenecks in Process

5: Future Purchase Plans

Time-Frame of Purchase Plans

• Overall
• By Brand/ Type Owned
• By Laboratory Function
• By Region

Systems Likely to Consider for Purchase

• Overall
• By Brand/ Type Owned
• By Industry/ Segment
• By Laboratory Function
• By Region

6: Company Profiles

• 10X Genomics
• BGI Genomics (formerly Beijing Genome Institute)
• Illumina
• Oxford Nanopore
• Promega Corporation
• QIAGEN N.V.
• Roche Diagnostics
• Swift Biosciences
• Thermo Fisher Scientific Inc.

Appendix: Library Preparation

For more information about this report visit https://www.researchandmarkets.com/r/6v0b8s

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.